| Literature DB >> 35681888 |
Jennifer Zahmel1, Kim Skalborg Simonsen2, Julia Stagegaard3, Sergio Eliseo Palma-Vera1, Katarina Jewgenow1.
Abstract
In the last 30-40 years, in vitro maturation (IVM) and fertilization (IVF) of domestic cat oocytes have been established as part of the panel of assisted reproduction technologies. As a representative of wild felids, the African lion is not yet considered endangered. Nevertheless, the zoo population management of the African lion itself as well as other closely related felids would benefit from the establishment of an IVF system. Here, we aimed to investigate the transferability of domestic cat IVF technology to the African lion. From the ovaries of 42 lionesses aged between 0.75 and 15 years, a total of 933 IVF-suitable oocytes were retrieved and subjected to IVM and IVF. The overall maturation rate was 40.6% and 18.9% of these oocytes cleaved after fertilization, respectively. Embryos were generated by intracytoplasmic sperm cell injection as well as co-culture with epididymal sperm. Improvements in the model system also led to an improved outcome with in vitro produced embryos in the lion. Compared to domestic cats, the transportation of gonads to a specialized laboratory was time-consuming and influenced oocyte quality negatively. In conclusion, the domestic cat IVF system is adoptable for the African lion, although success rates are still lower.Entities:
Keywords: African lion; assisted reproduction; domestic cat; in vitro fertilization; in vitro maturation
Year: 2022 PMID: 35681888 PMCID: PMC9179812 DOI: 10.3390/ani12111424
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Parameters and outcomes of IVF cascade for all lionesses.
| African Lion | Year | Age (years) | Transport (h) | n Oocytes | Duration of IVM (h) | n Matured Oocytes | Maturation Rate (%) | n Embryos | Ferilization Rate (%) | ICSI/IVF | Sperm Source | Utilized Media |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2007 | 5 | 28 | 22 | 36 | 6 | 27.3 | 0 | 0 | IVF | lion cryo | A1, C, E |
| 2 | 2008 | 15 | 24 | 31 | 36 | 2 | 6.5 | − | − | − | − | A1 (IVM only) |
| 3 | 2008 | 1 | 24 | 31 | 36 | 15 | 48.4 | − | − | − | − | A1 (IVM only) |
| 4 | 2009 | 13 | 5 | 4 | 36 | 0 | 0 | − | − | − | − | A1, C, E |
| 5 | 2009 | 7 | 10 | 36 | A1, E | |||||||
| 6 | 7 | 10 | 71 | 19 | 26.8 | 0 | 0 | ICSI | lion cryo | |||
| 7 | 7 | 10 | ||||||||||
| 8 | 2010 | 1 | 6 | 40 | 34 | 8 | 20 | 1 | 12.5 | ICSI | lion cryo | A1, E |
| 9 | 1 | 6 | ||||||||||
| 10 | 2010 | 5 | 24 | 26 | 28 | 5 | 19.2 | 2 | 40 | ICSI | tiger fresh | A1, E |
| 11 | 2011 | 8 | 10 | 35 | 0 | A1, C, E | ||||||
| 12 | 7 | 10 | 37 | 18 | 48.6 | 0 | IVF | lion cryo | ||||
| 13 | 6 | 10 | ||||||||||
| 14 | 2012 | 1 | 24 | 4 | 24 | 1 | 25 | 0 | 0 | ICSI | lion cryo | A1, E |
| 15 | 2012 | 1 | 24 | 3 | 24 | 0 | 0 | − | − | − | − | A1 |
| 16 | 2012 | 14 | 10 | 36 | 9.1 | |||||||
| 17 | 6 | 10 | 55 | 11 | 20 | 1 | ICSI | lion cryo | A1, E | |||
| 18 | 6 | 10 | ||||||||||
| 19 | 2013 | 1 | 10 | 70 | 34 | 25 | 35.7 | 11 | 44 | ICSI | lion cryo | A1, A2, F |
| 20 | 1 | 10 | ||||||||||
| 21 | 1 | 10 | ||||||||||
| 22 | 1 | 10 | ||||||||||
| 23 | 2014 | 0.75 | 24 | 10 | 28 | 4 | 40 | 0 | 0 | ICSI | lion cryo | A1, F |
| 24 | 2015 | 1 | 10 | 66 | 35 | 49 | lion cryo/ | A1, C, F | ||||
| 25 | 1 | 10 | 74.2 | 6 | 12.2 | ICSI/IVF | ||||||
| 26 | 1 | 10 | ||||||||||
| 27 | 2016 | 14 | 10 | 14 | 31 | 6 | 42.9 | 2 | 33.3 | IVF | lion cryo UC | A1, D, F |
| 28 | 2017 | 7 | 8 | 4 | 30 | 1 | 25 | 0 | 0 | ICSI | lion cryo | A1, F |
| 29 | 2018 | 11 | 28 | 23 | 25 | 5 | 21.7 | 0 | 0 | IVF | lion cryo | A1, D, F |
| 30 | 2019 | 7 | 24 | 8 | 24 | 3 | 37.5 | 0 | 0 | ICSI | lion cryo | A2, F |
| 31 | 2019 | 6 | 20 | 2 | 28 | 0 | 0 | − | − | − | − | A1 |
| 32 | 2019 | 7 | 0 | 9 * | 32−34 | 5 | 55.6 | 0 | 0 | ICSI | lion cryo | B, F |
| 33 | 2019 | 7 | 0 | 9 * | 32−34 | 1 | 11.1 | 0 | 0 | ICSI | lion cryo | B, F |
| 34 | 2019 | 5 | 0 | 28 * | 32−34 | 17 | 60.7 | 1 | 5.9 | ICSI | lion cryo | B, F |
| 35 | 2019 | 5 | 0 | 14 * | 32−34 | 10 | 71.4 | 2 | 20 | ICSI | lion cryo | B, F |
| 36 | 2020 | 1 | 0 | 54 | 30 | 8 | 44 | 0 | 0 | ICSI | lion fresh | B, F |
| 37 | 2021 | 13 | 0 | 10 | 28 | 5 | 50.0 | 3 | 60 | IVF | lion cryo | B, D, F |
| 38 | 2021 | 9 | 0 | 72 | 28 | 48 | 66.7 | 10 | 20.8 | IVF | lion cryo/fresh | B, D, F |
| 39 | 2021 | 9 | 0 | 17 | 28 | 15 | 88.2 | 3 | 20 | IVF | lion fresh | B, D, F |
| 40 | 2021 | 1 | 0 | 47 | 26/32 | 23 | 48.9 | 5 | 21.7 | IVF | lion cryo | B, D, G |
| 41 | 2021 | 1 | 0 | 23 | 29 | 14 | 60.9 | 6 | 42.9 | ICSI | lion cryo | B, G |
| 42 | 2021 | 1 | 0 | 70 | 26/32 | 31 | 44.3 | 11 | 35.5 | IVF | lion cryo | B, D, G |
| Total | Ø 5.3 | 874 (933) | 355 | 40.6 | 64 | 18.9 |
A, B, C…: different culture media in alphabetical order; A1, A2: Identical basic medium but different concentration of supplements.
Overview of media compositions utilized in this survey.
| Event | Basic Medium | Supplements | References |
|---|---|---|---|
| Transport: | |||
| T1 | Physiological saline solution | - | |
| T2 | Hepes-MEM (M7278) | 3 mg/mL BSA, 1:100 ( | [ |
| Washing medium: | |||
| WM | M199 (M4530) | 3 mg/mL BSA, 1.4 mg/mL HEPES, 0.6 mg/mL sodium lactate, 0.25 mg/mL sodium pyruvate, 0.15 mg/mL L-glutamine, 0.1 mg/mL cysteine and 0.055 mg/mL gentamicin | [ |
| IVM: | |||
| A1 | M199 (M4530) | WM + 0.05 IU/ml luteinizing hormone (LH) + 0.02 IU/ml pituitary follicle-stimulating hormone (FSH) | [ |
| A2 | M199 (M4530) | WM + 10x LH and FSH | [ |
| B | Quinn’s Advantage Protein Plus™ Blastocyst Medium (ART-1529) | + 10x LH and FSH | [ |
| IVF: | |||
| C | Tyrode’s salts solution (T2397) | 6 mg/mL BSA, 1.2 mg/mL HEPES, 1.1 mg/mL sodium lactate, 0.1 mg/mL sodium pyruvate, 0.15 mg/mL L-glutamine, 2.2 IU/mL Heparin | [ |
| D | M199 (M4530) | WM + 2.2 IU/mL Heparin | [ |
| IVC: | |||
| E | M16 | 3 mg/mL BSA, 0.03 mg/ml gentamicin, 0.1 mM non-essential amino acids | [ |
| F | HAM’s F10 (N6013) | 5% FBS, 0.11 mg/mL sodium pyruvate, 0.15 mg/mL L-glutamine, 0.06 mg/ml gentamicin | [ |
| G | Quinn’s Advantage Protein Plus™ Blastocyst Medium (ART-1529) | 5% FBS | [ |
| Sperm media: | |||
| H | Tyrode’s salts solution (T2397) | 6 mg/mL BSA, 1.2 mg/mL HEPES, 1.1 mg/mL sodium lactate, 0.1 mg/mL sodium pyruvate, 0.15 mg/mL L-glutamine | [ |
| I | M199 (M7528) | [ | |
| Mineral oil: | |||
| Sigma-Aldrich (M8410) | [ | ||
| Reprodline Medical GmbH (REF451200) | [ | ||
| Cooper Surgical (ART-4008-5) | not published |
T for Transport; WM for Washing medium; A, B, C…: different culture media in alphabetical order; A1, A2: Identical basic medium but different concentration of supplements.
Figure 1(A) Low cumulus expansion of African lion oocytes after 24 h in vitro maturation. (B) Cumulus expansion of domestic cat oocytes after 24 h in vitro maturation. (C) Sperm bound to zona pellucida after co-culture (African lion). (D) Early African lion morula, day 4.
Outcome of IVM and IVF from lion oocytes obtained from prepubertal (<2 years) and adult lionesses.
| Lionesses |
| No. of Oocytes | No. of Oocytes/Animal | Maturation Rate | Cleavage Rate |
|---|---|---|---|---|---|
| Prepubertals | 17 | 418 | 24.6 | 42.6% a | 24.5% a |
| Adults | 25 | 515 | 20.6 | 38.8% a | 13.7% b |
| Total | 42 | 933 | 22.2 | 40.6% | 18.9% |
Maturation rate and cleavage rate are presented as percentages based on the number of oocytes used in the respective experiments (in brackets). Different superscripts (a, b) within the same column indicate significant differences among groups (p < 0.05).
Cleavage and embryo development as outcomes of fertilization method. Due to the low numbers, statistical analysis of embryo development was omitted.
| Fertilization | No. of Matured Oocytes | Cleavage Rate | Stage of Embryo | |||
|---|---|---|---|---|---|---|
| 2–16 Cells | Morula | Blastocyst | ||||
| Co-Culture | 14 | 183 | 20.2% a | 33 [12] | 3 [3] | 1 [0] |
| ICSI | 26 | 155 | 17.4% a | 22 [5] | 1 [0] | 4 [1] |
| Total | 40 | 338 | 18.9% | 55 | 4 | 5 |
Cleavage rates are presented as percentages based on the number of oocytes used in the respective experiments (in brackets). Numbers of vitrified embryos of the different stages are depicted in square brackets. Due to the low numbers, statistical analysis of embryo development was omitted. Different superscripts (a, b) within the same column indicate significant differences among groups (p < 0.05).
Impact of time between retrieval of gonads and oocytes collection. For transportation, ovaries were stored in physiological salt solution in a Styrofoam box equipped with cool packs.
| Transport Duration | Mean Age of Lionesses | No. of Oocytes | Maturation Rate | Cleavage Rate | |
|---|---|---|---|---|---|
| 0 h | 11 | 5.3 | 412 | 50.1% | 23.2% |
| 10 h | 21 | 5.3 | 361 | 38.0% | 15.3% |
| 24–28 h | 10 | 5.3 | 160 | 25.6% | 8.3% |
Maturation rates and cleavage rates are presented as percentages based on the number of oocytes used in the respective experiments (in brackets).
Effects of the duration of IVM in African lion oocytes.
| Maturation Time | No. of Oocytes | Matured Oocytes | Cleaved Embryos | |
|---|---|---|---|---|
| 24–28 h | 13 | 235 | 115 a | 29 a |
| 32–36 h | 28 | 544 | 211 b | 27 b |
Different superscripts (a, b) within the same column indicate significant differences among groups (p < 0.05).